> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Yumanity Parkinson’s Trial Hold
- URL: https://www.fdaweb.com/fda-yumanity-parkinsons-trial-hold/
- Published: 2022-01-19T12:00:00.000Z
- Updated: 2026-09-14T17:29:07.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5150954

FDA has placed a partial clinical hold on multi-dose clinical trials of Yumanity Therapeutics’ YTX-7739 that is being developed to treat Parkinson’s disease. The company [says](https://yumanity.gcs-web.com/news-releases/news-release-details/yumanity-reports-partial-clinical-hold-us-fda-multidose-clinical?ref=fdaweb.com) the agency has not halted all clinical programming and is permitting Yumanity to proceed with its planned single-dose clinical trial. “The partial clinical hold suspends initiation of multiple-dose clinical trials in the U.S. until FDA’s questions have been answered,” the company says.

Yumanity says YTX-7739 is its proprietary lead small molecule investigational therapy designed to penetrate the blood-brain barrier and inhibit the activity of a novel target, stearoyl-CoA desaturase.